Streamlined.financeStreamlined.finance
MarketsFind Stocks

OKYO Pharma Limited

NASDAQ

Market Cap.

38.29M

Avg. Volume

197.87K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about OKYO Pharma Limited

OKYO Pharma Limited News

OKYO Pharma Limited Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareBiotechnology
okyopharma.com

About OKYO Pharma Limited

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited Earnings & Revenue

OKYO Pharma Limited Financials

Table Compare

Compare OKYO metrics with:

   

Earnings & Growth

OKYO

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

OKYO

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

OKYO

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

OKYO

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

OKYO Pharma Limited Income

OKYO Pharma Limited Balance Sheet

OKYO Pharma Limited Cash Flow

OKYO Pharma Limited Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsNeutral
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

OKYO Pharma Limited Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

OKYO Pharma Limited Executives

NameRole
Dr. Gary S. Jacob Ph.D.Chief Executive Officer & Executive Director
Mr. Michael Paul BeckFounder
Dr. Rajkumar Patil Ph.D.Chief Scientific Officer
Ms. Keeren ShahChief Financial Officer
NameRoleGenderDate of BirthPay
Dr. Gary S. Jacob Ph.D.Chief Executive Officer & Executive Director1947588K
Mr. Michael Paul BeckFounderMale1957

--

Dr. Rajkumar Patil Ph.D.Chief Scientific Officer1959

--

Ms. Keeren ShahChief Financial OfficerFemale1975

--

OKYO Pharma Limited Insider Trades

Date23 Oct
NameCERRONE GABRIELE M
RoleExecutive Chairman
TransactionAcquired
TypeJ-Other
Shares499468
Date27 Oct
NameCERRONE GABRIELE M
RoleExecutive Chairman
TransactionAcquired
TypeJ-Other
Shares70071
Date15 Sep
NameBRANCACCIO JOHN P
RoleDirector
TransactionAcquired
TypeP-Purchase
Shares16670
Date19 May
NameCERRONE GABRIELE M
RoleExecutive Chairman
TransactionAcquired
TypeP-Purchase
Shares5800000
Date19 May
NameJACOB GARY S
RoleChief Executive Officer
TransactionAcquired
TypeP-Purchase
Shares12500
DateNameRoleTransactionTypeShares
23 OctCERRONE GABRIELE MExecutive ChairmanAcquiredJ-Other499468
27 OctCERRONE GABRIELE MExecutive ChairmanAcquiredJ-Other70071
15 SepBRANCACCIO JOHN PDirectorAcquiredP-Purchase16670
19 MayCERRONE GABRIELE MExecutive ChairmanAcquiredP-Purchase5800000
19 MayJACOB GARY SChief Executive OfficerAcquiredP-Purchase12500

Discover More

Streamlined Academy

OKYO Pharma Limited

NASDAQ

Market Cap.

38.29M

Avg. Volume

197.87K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

OKYO Pharma Limited News

OKYO Pharma Limited Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

OKYO Pharma Limited Earnings & Revenue

OKYO Pharma Limited Income

OKYO Pharma Limited Balance Sheet

OKYO Pharma Limited Cash Flow

OKYO Pharma Limited Financials Over Time

OKYO Pharma Limited Executives

NameRole
Dr. Gary S. Jacob Ph.D.Chief Executive Officer & Executive Director
Mr. Michael Paul BeckFounder
Dr. Rajkumar Patil Ph.D.Chief Scientific Officer
Ms. Keeren ShahChief Financial Officer
NameRoleGenderDate of BirthPay
Dr. Gary S. Jacob Ph.D.Chief Executive Officer & Executive Director1947588K
Mr. Michael Paul BeckFounderMale1957

--

Dr. Rajkumar Patil Ph.D.Chief Scientific Officer1959

--

Ms. Keeren ShahChief Financial OfficerFemale1975

--

OKYO Pharma Limited Insider Trades

Date23 Oct
NameCERRONE GABRIELE M
RoleExecutive Chairman
TransactionAcquired
TypeJ-Other
Shares499468
Date27 Oct
NameCERRONE GABRIELE M
RoleExecutive Chairman
TransactionAcquired
TypeJ-Other
Shares70071
Date15 Sep
NameBRANCACCIO JOHN P
RoleDirector
TransactionAcquired
TypeP-Purchase
Shares16670
Date19 May
NameCERRONE GABRIELE M
RoleExecutive Chairman
TransactionAcquired
TypeP-Purchase
Shares5800000
Date19 May
NameJACOB GARY S
RoleChief Executive Officer
TransactionAcquired
TypeP-Purchase
Shares12500
DateNameRoleTransactionTypeShares
23 OctCERRONE GABRIELE MExecutive ChairmanAcquiredJ-Other499468
27 OctCERRONE GABRIELE MExecutive ChairmanAcquiredJ-Other70071
15 SepBRANCACCIO JOHN PDirectorAcquiredP-Purchase16670
19 MayCERRONE GABRIELE MExecutive ChairmanAcquiredP-Purchase5800000
19 MayJACOB GARY SChief Executive OfficerAcquiredP-Purchase12500

Streamlined Academy

Website screenshot
HealthcareBiotechnology
okyopharma.com

About OKYO Pharma Limited

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about OKYO Pharma Limited

OKYO Pharma Limited Financials

Table Compare

Compare OKYO metrics with:

   

Earnings & Growth

OKYO

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

OKYO

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

OKYO

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

OKYO

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

OKYO Pharma Limited Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsNeutral
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)